Curt LaBelle

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Curt LaBelle
Curt LaBelle
Non-Executive Director / Atomo Diagnostics

Dr Curt LaBelle has been involved in the healthcare industry for over 20 years, both operationally and as an investor.

Dr LaBelle is president of the Global Health Investment Fund (GHIF) and a company director of Alydia Health, Evenovia and Atticus Medical. Prior to joining GHIF, Dr LaBelle was the managing director of Tullis Health Investors and vice president of Investor Growth Capital. He was also chair of Impulse Monitoring (acquired by Nuvasive) and NASDAQ-listed Exagen; and director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen).

Lists and Charts

Knowledge Bank : Person Roles

2016
Non-Executive Director
Atomo Diagnostics
Year started and most recent title

Total Shareholder Return as at 06/01/26

Rank Company 1 Yr 5 Yr
Atomo Diagnostics 89.65% -34.76%
View Full List
1658 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

11/04/23
Other
Atomo Diagnostics
06/04/22
Other
Atomo Diagnostics
09/04/21
$150.00k Other
Atomo Diagnostics
Total value as at the date of the transaction
Powered by Morningstar ®

    Related Information

    Access to our data for Curt LaBelle is only available to paid subscribers with Data & Insights access.

    Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

    Curt LaBelle is linked to 1 organisation which is included in 1 list - Public Companies - non WA.

    To see the data you will need to Subscribe.

    X